Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.53 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22795390 | 1.00 | OPRM1 (0.53) | OPRM1OPRL1KDM2BOPRK1OPRD1 | |
| SCHEMBL22795400 | 1.00 | OPRM1 (0.53) | OPRM1OPRL1KDM2BOPRK1OPRD1 | |
| SCHEMBL22795479 | 0.88 | OPRM1 (0.52) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| SCHEMBL22795478 | 0.88 | OPRM1 (0.52) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| SCHEMBL22795419 | 0.88 | OPRM1 (0.52) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| SCHEMBL24539996 | 0.82 | KDM2B (0.43) | OPRM1OPRL1KDM2BOPRK1OPRD1 | |
| SCHEMBL22795215 | 0.82 | KDM2B (0.43) | OPRM1OPRL1KDM2BOPRK1OPRD1 | |
| SCHEMBL22795396 | 0.82 | KDM2B (0.43) | OPRM1OPRL1KDM2BOPRK1OPRD1 | |
| SCHEMBL22795401 | 0.82 | KDM2B (0.43) | OPRM1OPRL1KDM2BOPRK1OPRD1 | |
| SCHEMBL22795402 | 0.82 | KDM2B (0.43) | OPRM1OPRL1KDM2BOPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12115154-B2 | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) | SRX CARDIO, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| US-20220267269-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | OPRM1 4709/4885OPRL1 4250/4885KDM2B 4148/4885 |
| US-12115154-B2 | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | OPRM1 4709/4885OPRL1 4250/4885KDM2B 4148/4885 |
| US-20220267269-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | OPRM1 4709/4885OPRL1 4250/4885KDM2B 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.